Patents by Inventor Svetlana Pavlova Ikonomova

Svetlana Pavlova Ikonomova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Histatin-5 based synthetic peptides and uses thereof
    Patent number: 10464977
    Abstract: Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiological condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: November 5, 2019
    Assignees: University of Maryland, Baltimore, University of Maryland, College Park
    Inventors: Mary Ann Jabra-Rizk, Amy J. Karlsson, Svetlana Pavlova Ikonomova
  • Histatin-5 Based Synthetic Peptides and Uses Thereof
    Publication number: 20170291930
    Abstract: Provided herein are synthetic peptides or synthetic fragments thereof based on a Histatin-5 peptide, for example with a sequence DSHAKRHHGYKRKFHEKHHSHRGY (SEQ ID NO: 1). The synthetic peptides or synthetic fragments have at least one substituted amino acid that is arginine and/or leucine to increase resistance to proteolytic degradation by a microbe, such as a fungus. The synthetic peptides or synthetic fragments thereof may be contained in a hydrogel. Also provided are methods for treating or preventing a pathophysiologica condition via topical administration of the synthetic peptide or fragments. The pathophysiological condition may be a fungal or bacterial infection including associated inflammation or a chronic condition.
    Type: Application
    Filed: April 11, 2017
    Publication date: October 12, 2017
    Applicants: University of Maryland, Baltimore, University of Maryland, College Park
    Inventors: Mary Ann Jabra-Rizk, Amy J. Karlsson, Svetlana Pavlova Ikonomova